阿斯利康/第一三共Trop2靶向ADC获FDA优先审评资格阿斯利康(AstraZeneca)与第一三共(Daiichi Sankyo)宣布,其Trop2靶向抗体偶联药物(ADC)Datroway(datopotamab deruxtecan)的补充生物制品许可申请(sBLA)已获美国FDA受理,并被授予优先审评资格,用于治疗无法切除或转移性三阴性乳腺癌(TNBC)成人患者,这些患者不适合接受PD-...
Source Link阿斯利康/第一三共Trop2靶向ADC获FDA优先审评资格阿斯利康(AstraZeneca)与第一三共(Daiichi Sankyo)宣布,其Trop2靶向抗体偶联药物(ADC)Datroway(datopotamab deruxtecan)的补充生物制品许可申请(sBLA)已获美国FDA受理,并被授予优先审评资格,用于治疗无法切除或转移性三阴性乳腺癌(TNBC)成人患者,这些患者不适合接受PD-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.